CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞的高成本：挑战与解决方案
英文原题：High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions.
查看英文原题
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞是一种细胞免疫疗法，在治疗多种血液系统恶性肿瘤方面具有显著疗效，但其价格极高，对许多国家而言昂贵到无法承受。随着其在血液系统恶性肿瘤及其他适应症中的应用不断增加，以及大量新型细胞疗法被开发出来，既需要降低治疗成本，也需要解决支付问题，因此需要新的方法。我们综述了导致CAR-T 细胞高成本的诸多因素，并提出改革建议。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cells are a cellular immunotherapy with remarkable efficacy in treating multiple hematologic malignancies but they are associated with extremely high prices that are, for many countries, prohibitively expensive. As their use increases both for hematologic malignancies and other indications, and large numbers of new cellular therapies are developed, novel approaches will be needed both to reduce the cost of therapy, and to pay for them.
We review the many factors that lead to the high cost of CAR T-cells and offer proposals for reform.
论文信息
- 作者
- Cliff ERS、Kelkar AH、Russler-Germain DA、Tessema FA、Raymakers AJN、Feldman WB、Kesselheim AS
- 单位
- Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.United States
- 文献类型
- 综述
- 期刊
- American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2023 Jun
- 原文标识
- PubMed 37433102 · DOI 10.1200/EDBK_397912